Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
- 28 June 2019
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 38 (31) , 5921-5932
Abstract
The incorporation into clinical practice of immune-checkpoint inhibitors (ICIs), such as those targeting the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) and its ligand (PD-L1), has represented a major breakthrough in non-small cell lung cancer (NSCLC) treatment, especially in cases where the cancer has no druggable genetic alterations. Despite becoming the standard of care in certain clinical settings, either alone or in combination with chemotherapy, a proportion of patients do not respond while others actually progress during treatment. Therefore, there is a clinical need to identify accurate predictive biomarkers and to develop novel therapeutic strategies based on ICIs. Although they have limitations, the current markers evaluated to select which patients will undergo ICI treatment are the levels of PD-L1 and the tumor mutational burden. In this paper we describe what is currently known about the dynamic interaction between the cancer cell and the immune system during carcinogenesis, with a particular focus on the description of the functions and gene alterations that preclude the host immunoresponse in NSCLC. We emphasize the deleterious gene alterations in components of the major histocompatibility complex (HLA-I or B2M) and of the response to IFNγ (such as JAK2) which are mutually exclusive and can affect up to one fifth of the NSCLCs. The participation of other gene alterations, such as those of common oncogenes and tumor suppressors, and of the epigenetic alterations will also be discussed, in detail. Finally, we discuss the potential use of the tumor’s genetic profile to predict sensitivity to ICIs.Keywords
Funding Information
- Fundación Científica Asociación Española Contra el Cáncer (GCB14142170MONT)
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2014-54571-R)
- Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Rio Hortega Contract)
This publication has 81 references indexed in Scilit:
- Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomasNature Genetics, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Inhibitory Roles of Signal Transducer and Activator of Transcription 3 in Antitumor Immunity during Carcinogen-Induced Lung TumorigenesisCancer Research, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndromeOncogene, 2007
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- The roles of IFNγ in protection against tumor development and cancer immunoeditingCytokine & Growth Factor Reviews, 2002
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent miceProceedings of the National Academy of Sciences, 1998
- Cancer--A Biological Approach: III. Viruses Associated with Neoplastic Conditions. IV. Practical ApplicationsBMJ, 1957